E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/1/2006 in the Prospect News Biotech Daily.

RBC ups Pozen price target to $20

RBC Capital Markets analyst Ken Trbovich reiterated Pozen, Inc. at outperform, speculative risk, and raised the price target to $20 from $15. The company reported a net loss of $0.14 compared to RBC's estimate of $0.14 including non-cash stock-based compensation expense. The analyst will be including stock-based compensation expense in estimates going forward. Shares of the Chapel Hill, N.C.-based development-stage company were down 45 cents, or 2.71%, at $16.18. (Nasdaq: POZN)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.